Our Take
This is vendor-led selection advice packaged as framework, not a gap analysis; it tells you what to ask, not what most CDMOs actually fail at.
Why it matters
CDMO partnerships now determine whether drug programmes stay on timeline or stall in scale-up. Multi-vendor fragmentation creates data silos and accountability gaps that worsen as complexity increases.
Do this week
Clinical ops lead: audit your current CDMO against the seven criteria (lifecycle continuity, complexity at scale, data visibility, tech transfer maturity, regulatory readiness, governance, cultural fit) before your next phase gate review so you can identify coordination gaps before they compound.
87% of biopharma companies now outsource at least part of development or manufacturing
For emerging and mid-sized biopharma, selecting a CDMO partner has become a strategic decision that can determine programme velocity or introduce delays before a product reaches commercial manufacturing. The industry increasingly faces a choice: fragmented multi-vendor models or integrated CDMO-CRO partnerships that span early development through commercial scale.
Multi-vendor approaches introduce structural friction. Managing multiple vendors increases coordination complexity, creates data silos, and weakens accountability. Early-stage programmes perceive smaller CMOs as more agile, but as programmes progress to later phases, these inefficiencies compound. GlobalData analysis shows that a relatively small number of large CMOs capture a significant share of commercial manufacturing contracts for approved products, signalling a shift toward scale and reliability (per GlobalData).
Integrated CDMOs now offer end-to-end capabilities: process development, clinical and commercial manufacturing, supply chain management, and regulatory strategy within a single execution framework. The advantage is not flexibility traded for scale, but both improved together through reduced operational fragmentation and consistent application of process knowledge across development stages.
CDMO selection now requires evaluation across operational continuity, not just capability checklists
Drug development pipelines are diversifying across modalities, regulatory scrutiny is intensifying, and the margin for error in execution is shrinking. Early-phase trials present particular complexity: 29% of planned clinical trials for 2026 are phase I, and delivering these on a global scale involves fragmented regulatory requirements, limited GMP-grade material availability, and logistical constraints that can stall site activation and dose escalation.
The cost of coordination failure is non-negotiable. Differing regulatory requirements across jurisdictions, disparate pharmacovigilance frameworks, data privacy restrictions (including GDPR), and misaligned timelines between development and manufacturing sites introduce unpredictability into cost management and compliance risk. Sponsors selecting partners based on single-capability strength (analytical capability, manufacturing capacity) without assessing how process knowledge transfers across teams and sites often encounter disruption as programmes scale.
Ask these seven questions before committing to a CDMO partnership
Lifecycle continuity: How will early design choices be maintained and scaled through commercialisation? Demand evidence of process knowledge retention across development, manufacturing, regulatory, and commercial teams.
Complexity at scale: Does the CDMO have proven experience across small molecules, biologics, and advanced therapies without creating additional vendor dependencies?
Data visibility and decision support: Can the CDMO provide integrated programme visibility, timely reporting, and risk identification tools during development and scale-up, or do you need separate analytics platforms?
Tech transfer maturity: How many successful tech transfers has the CDMO completed? Ask for specific examples of analytical comparability, risk-mitigation strategies, and documentation standardisation across sites.
Regulatory readiness: Does the CDMO have documented experience with accelerated pathways, global submissions, pharmacovigilance requirements, and inspection management across your target jurisdictions?
Governance and accountability: Are programme leads designated, escalation processes transparent, and ownership of risks clearly assigned in writing?
Cultural fit and collaboration: How does the CDMO handle supply constraints, technical setbacks, and regulatory queries? This determines whether momentum survives the inevitable obstacles.